Description
Azashine 100 mg contains Azacitidine, a nucleoside metabolic inhibitor classified as a hypomethylating agent. It is administered via subcutaneous or intravenous injection under hematologist supervision and is widely used in the management of bone marrow disorders.
🔬 Mechanism of Action
Azacitidine incorporates into DNA and RNA of abnormal cells. As a result:
- DNA methylation is reduced
- Tumor suppressor genes may be reactivated
- Abnormal bone marrow cell growth is inhibited
- Normal blood cell production improves
This dual action makes it effective in treating myeloid malignancies.
💊 Indications of Azashine 100 mg
Azashine 100 mg is indicated for:
- Myelodysplastic Syndromes (MDS)
- Acute Myeloid Leukemia (AML) (particularly in elderly or unfit patients)
- Chronic Myelomonocytic Leukemia (CMML)
📌 Key Features of Azashine 100 mg
- Strength: 100 mg
- Dosage Form: Powder for injection
- Therapeutic Class: Hypomethylating Agent / Antimetabolite
- Administration: Subcutaneous or intravenous injection in repeated treatment cycles
- Typical Regimen: 7-day treatment cycle every 28 days (as prescribed)
- Monitoring: Regular complete blood count (CBC) and liver/kidney function tests required
⚕️ Benefits of Azacitidine
- Improves overall survival in high-risk MDS and AML
- Enhances bone marrow function
- Reduces transfusion dependence
- Suitable for elderly or high-risk patients
⚠️ Precautions
- Risk of myelosuppression (anemia, neutropenia, thrombocytopenia)
- Nausea, vomiting, injection site reactions may occur
- Regular blood monitoring essential
- Use strictly under hematologist supervision
Azashine 100 mg (Azacitidine Injection) is a vital treatment option in modern hematology, helping manage high-risk myelodysplastic syndromes and acute myeloid leukemia by restoring normal bone marrow function under specialized medical care.
